Prognostic Value of Long Noncoding RNA NORAD in Various cancers: a metaanalysis

Qin Yang $^{a,\,b,\,1},$ Zheng Zhang $^{c,\,1},$ Yuan-Yuan Gong $^{a,\,b,\,1},$ Zhi-Ran Li $^{a,\,b},$ Hua-Zhu

Zhang a, b, Gong-Hao He a, b, *

^a Research Center of Clinical Pharmacology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650032, China.

^b Department of Pharmacy, 920th Hospital of Joint Logistics Support Force, 212

Daguan Rd., Kunming 650032, China.


^c Medical Engineering Section, The 306th Hospital of PLA, Beijing 100101, China.

Running title: lncRNA NORAD with prognosis of cancer patients

Tel: +86-871-64774793, E-mail: gonghow@hotmail.com.

¹ These authors contributed equally to this work.

^{*} Correspondence to: Gong-Hao He, Ph.D., 212 Daguan Rd, Kunming 650032, China.



Supplementary Figure S3. Survival curves of NORAD in various types of cancers from TCGA database. (a) The overall survival curve of patients with diverse cancers; (b) The disease-free survival curve of patients with diverse cancers.